Immune response to liver perfusion therapy for eye melanoma
Part of Cancer, Eyes & vision clinical trials.
This study tests how well the liver responds to a treatment called percutaneous hepatic perfusion with melphalan (chemotherapy delivered directly to the liver) in people with uveal melanoma that has spread to the liver. The goal is to see how the immune system reacts and if the treatment helps control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have uveal melanoma (an eye cancer) that has spread to the liver.
- You are physically well enough to have a daily activity score of 0 or 1 (fully active to slightly restricted).
- You have at least one liver tumor that is 1 cm or larger and can be biopsied.
- Your blood tests show adequate kidney and liver function and normal blood cell counts.
- You are not pregnant, breastfeeding, or taking medications that increase bleeding risk.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a liver-directed therapy (PHP) to a combination of two immunotherapy drugs (ipilimumab and nivolumab) works better than the immunotherapy drugs alone for people whose uveal melanoma has spread to the liver.
This study uses your own immune cells (called TILs) to fight melanoma that has spread to the liver. Doctors will remove a piece of the tumor, grow the immune cells in a lab, and give them back to you to help shrink the cancer.
This trial tests immunotherapy before surgery for people with high-risk eye melanoma (uveal melanoma). You’ll get treatment to help your immune system fight the cancer, then have your eye removed. After surgery, you’ll be followed to see how well the treatment worked.
This early-phase study tests whether melphalan can be used to reduce (shrink) a type of eye cancer called choroidal melanoma before additional treatment. It may help by controlling tumor size while doctors closely monitor the eye and outcomes.
This trial tests a new drug (RBP-01) given before standard treatment for uveal melanoma, a type of eye cancer. The goal is to see if the drug can shrink the tumor or improve outcomes for people who need eye removal or high-risk radiation therapy.
This trial tests a two-part treatment for uveal melanoma that has spread to the liver. First, you get a liver-directed chemotherapy (melphalan) through a special procedure called PHP, then you receive an immunotherapy drug (tebentafusp) that helps your immune system attack the cancer.
Hear when a new Uveal Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.